

Organisation

Unit Head and Principal Investigator

Dr. P.D. Aude Ambresin

Clinical Research Coordinators

Daniela Gallo Castro, PhD

Yannic Pannatier-Schuetz, PhD

Optometrist Referent

Lucie Faillot

Nurse Referent

Alexandrina Oliveira Fernandes

Data Scientist

Baptiste Crozat

Biostatistician

Pathé Barry

Medical Fellows

Dr. Konstantinos Kitsos-Kalyvianakis (2025)

Dr. Sila Bekiroglu (2025)

Dr. Nicolo Bartolomeo (2024)

Dr. Mihaela Chitoroaga (2023)

Dr. Nicolas Owlya (2022)

Dr. Mickael Barbosa (2022)

Dr. Coraline Calci (2021)

Dr. Georgios N. Tsiropoulos (2020)

Dr. Vasilea Chatzistergiou (2019)

Dr. Giorgio E. Bravetti (2018)

Dr. Ioannis Papasavvas (2017)

TEACHING

University of Lausanne

- Ambresin A. (every year since 2015) Gène et Vision [University course M1] [2022 evaluation: 100% satisfaction]. Medical Faculty, University of Lausanne; Switzerland

Montchoisi B Center

- Ambresin A. Angiography. Montchoisi B Center; Lausanne, Switzerland.
- Ambresin A. Fluorescein and OCT. Montchoisi B Center; Lausanne, Switzerland.
- Ambresin A. Journal Club Retina. Montchoisi B Center; Lausanne, Switzerland.
- Ambresin A. Retinal Circulation, Vein Occlusion, and Diabetic Retinopathy. Montchoisi B Center; Lausanne, Switzerland.
- Ambresin A. Retinal Imagery. Montchoisi B Center; Lausanne, Switzerland.

Jules Gonin Eye Hospital

- Ambresin A. Fluorescein Angiography and OCT. Jules Gonin Eye Hospital; Lausanne, Switzerland.

Others

- Ambresin A. Les complications du diabète - Rétinopathie. Cours pour expert·e en conseil de diabétologie. Hôpital de Lavaux; 2023 Nov 15 and 2024 Dec 12; Cully, Switzerland.

MULTICENTRIC studies

Completed

- SANDCAT (Roche) - A Phase III, Multicenter, Randomized, Double Masked, Sham-controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Anti-IL6 in Adult Patients with Uveitic Macular Edema. 2024-2025.
- PULSAR (Bayer) - Randomized, Double-Masked, Active-Controlled, Multi-Center Study of Efficacy and Safety of Intravitreal High Dose Aflibercept (8 mg) in Patients with Neovascular Age-Related Macular Degeneration. PI. 2021-2024.
- INTERCEPT - AMD - A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate AMD with and without Early Atrophy to Study Prediction of Disease Progression. Collaboration with: EVICR.net; 2023-2024.
- Multicentric Retrospective Study on Response to Brolucizumab in Treatment-naïve and Pre-treated Eyes Diagnosed with Wet AMD. Collaboration with: Berner Augenklinik am Lindenhofspital; 2022.
- Consensus visual OCT priming study wetAMD. In collaboration with: Institute of Molecular and Clinical Ophthalmology Basel, the University Hospital Basel and the University of Applied Sciences Northwestern Switzerland; 2022.
- Global nAMD & DR Barometer Survey. A multi-country patient and clinician survey to investigate patients' and clinical peers' perspectives, trends and practice patterns, relevant to the delivery of care for nAMD and DR. 2022.
- Real-Life Outcomes of adjunct intravitreal Dexamethasone Implant (Ozurdex) in Patients treated with anti-VEGF drugs for Diabetic Macular Edema and Exudative Age-Related Macular Degeneration. In collaboration with: Berner Augenklinik am Lindenhofspital. 2022.
- FALCON (Novartis) - A 52-week, two arm, randomized, open-label, multicenter study assessing the efficacy and safety of two different brolucizumab 6 mg dosing regimens for patients with suboptimal anatomically controlled neovascular age-related macular degeneration. PI. 2021-2022.
- PI for: The brolucizumab RAPTOR BRVO study RTH258C2301 (Novartis) - An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Branch Retinal Vein Occlusion. 2019-2021.
- XTEND (Bayer) – Evaluation of an eXtended and proacTive dosing regimEn in treatment-Naïve patients with wet age-related macular Degeneration (wAMD). PI. 2019.
- PI for: A Phase 2, randomised, single-masked, active-controlled, multicentre study to evaluate the efficacy and safety of intravitreal THR-317 administered in combination with ranibizumab, for the treatment of diabetic macular oedema (DME). 2018-19.
- Principal Investigator (PI) for: Allergan Abicipar Pegol 150998-005 (CEDAR) Study: The Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age related Macular Degeneration. 2016-2017.
- Sub-principal Investigator (Sub-PI) for: Efficacy and Safety of RTH258 versus Aflibercept Long Title A Two-Year, Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration. 2015-2017.
- Principal Investigator (PI) for: A 12-month, phase III, randomized, double-masked, multi-center, active-controlled study to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab vs. verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia. Mont Blanc Study.
- Principal Investigator (PI) for: A 12-month phase III study to evaluate efficacy and safety of two different dosing regimen of 0.5mg ranibizumab vs verteporfin PDT in patients with visual impairment due to choroidal CNV secondary to pathologic myopia. Radiance Study.
- Sub-principal Investigator (Sub-PI) for: A phase 3, randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreal Administration of Fovista (anti PDGF-B

Pegylated Aptamer) Administered in Combination with Lucentis Compared to Lucentis Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration Fovista.

- Sub-principal Investigator (Sub-PI) for: A 24-month phase IIIb randomized multicenter study assessing safety and efficacy of two treatment regimens of 0.5mg ranibizumab intravitreal guided by functional and /or anatomical criteria in patients with neovascular AMD (OCTAVE).
- Sub-principal Investigator (Sub-PI) for: A 12-month, phase IIIb, randomized, visual acuity assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in TReat and extEND regimen compared to monthly regimen, in patients with neovascular age-related macular degeneration.
- Sub-principal Investigator (Sub-PI) for: A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven macular edema (ME). Prometheus study.
- Sub-principal Investigator (Sub-PI) for: A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV). Minerva Study.
- Principal Investigator (PI) for: A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy in patients with visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO). Crystal Study.
- Principal Investigator (PI) for: A 24-month, phase IIIb, open-label, randomized, active controlled, 3-arm, multicenter study assessing the efficacy and safety of an individualized, stabilization-criteria-driven PRN dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy or with adjunctive laser photocoagulation in comparison to laser photocoagulation in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO) Brighter.

Ongoing

- GALAXY (ONL Therapeutics) – A Phase 2 Multicenter, Randomized, Double-masked, Sham-controlled, Active-reference Study to evaluate Efficacy and Safety of ONL1204 in Patients with Geographic Atrophy (GA) associated with Age-related Macular Degeneration (AMD). PI 2025-2026.
- QUASAR (Bayer) - Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion. PI. 2023-2025.
- Real-Life Outcomes in Diabetic Macular Edema and Exudative Age-Related Macular Degeneration treated with Faricimab and/or Aflibercept 8mg. PI.
- VOYAGER (Roche) - Real-world, Long-term Data Collection to Gain Clinical Insights into Roche Ophthalmology Products. PI.
- SPECTRUM (Bayer) - An Observational Study Program to Investigate the Effectiveness of Aflibercept 8mg Used in nDME and nAMD in a Real-world Setting.PI.
- AI-based Analysis of Retinal Imaging Data of Real-World Evidence in Switzerland. PI.

MONOCENTRIC STUDIES

Completed

- Efficacy and Durability of Faricimab Intravitreal Injections in Naïve Patients With Wet Age-related Macular Degeneration.
- Switch From Aflibercept to Faricimab in Patients With Neovascular Age-related Macular Degeneration.
- Evolution of Acute Intraocular Pressure Elevations Following Intravitreal Anti-VEGF Injections Over One Year of Treatment. IOP.
- COVID AMD - Patient Opinion on the Monitoring of Their Wet Age-related Macular Degeneration During Coronavirus Disease 2019 Pandemic and on the Importance of Telemedicine.
- COVID AMD - The Importance of Monitoring Wet AMD Patients During Covid-19 Pandemic: a Retrospective Study of Assessment of Functional and Structural Outcomes.
- COVID-RV –Five Cases of Retinal Vascular Anomalies After Covid-19: a Case Series.
- Influence des variations des temps circulatoires rétiens et choroïdiens mesurés en angiographie avec produit de contraste sur l'analyse quantitative obtenue en OCT-angiographie.
- Fovea Plana / Hypoplasia - Foveal Hypoplasia on Optical Coherence Tomography Angiography: New Perspectives.
- AZM RD - Optical Coherence Tomography Analysis of Cystoid Macular Edema in Retinal Dystrophy Treated with Oral Acetazolamide: Two Cases.
- Vitamin A Deficiency - Markedly Delayed Night Blindness Due to Vitamin A Insufficiency Secondary to Bowel Resection.
- Influence of Structural Spectral-domain Optical Coherence Tomography Characteristics in the Detection of Choroidal Neovascularization Due to Age-related Macular Degeneration Using Optical Coherence Tomography Angiography.

Ongoing

- Evaluation of geographic atrophy (GA) lesion size and growth rates measurements using semiautomated and artificial intelligence (AI) software.
- Real-world Observational Data on the Use of Aflibercept 8mg Intravitreal Injection in Patients Treated for Exudative Age-related Macular Degeneration and Diabetic Macular Edema.
- Intravitreal Faricimab in Patients Treated for Refractory Diabetic Macular Edema.

PUBLICATIONS (SINCE 2015)

Peer-reviewed

- Hatz K, Ambresin A, Schmid M, Prünke C, Barthelmes D, Machewitz T, Allmeier H, Somfai GM on behalf of the XTEND Study Group. Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration. *Journal of Clinical Medicine*. 2025; 14(7):2370. <https://doi.org/10.3390/jcm14072370>
- Grimaldi G, Ambresin A, Pfister IB, Schild C, Plasencia C, Hatz K, Stillenmunkes R, Munk MR, Paris A, Menghini M, Artemiev D, Ebnetter A, Cattaneo J, de Oliveira Figueiredo EC, Eandi CM, Fröhlich J, Feltgen N, Spitznagel T, Somfai GM, Cozzi M, Zweifel S, Weinberger A, Garweg JG. One-Year Outcomes after Switching to Faricimab in Eyes with Pretreated Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report. *Ophthalmol Retina*. 2025 Mar 24:S2468-6530(25)00124-1. doi: 10.1016/j.oret.2025.03.015. Epub ahead of print. PMID: 40139459.
- Chitoroaga M, Schuetz Pannatier Y, Gallo Castro D, Nascimbeni AC, Ambresin A. Long-term Follow-up of Outer Retinal Microdefects (ORMDs) in Pachychoroid Pigment Epitheliopathy (PPE) and Subsequent Central Serous Chorioretinopathy (CSCR): A Report of Two Cases. *Klin Monbl Augenheilkd*. 2025 Apr;242(4):418-420. English. doi: 10.1055/a-2500-5687. Epub 2025 Feb 27. PMID: 40015307.
- Bartolomeo N, Déglise A, Schuetz YP, Castro DG, Nascimbeni AC, Ambresin A. Retinal Toxicity of Anticancer Drugs: A Case Series. *Klin Monbl Augenheilkd*. 2025 Apr;242(4):429-431. English. doi: 10.1055/a-2521-4104. Epub 2025 Feb 27. PMID: 40015303.
- Ben Ghezala I, Steinberg LA, Sibert M, Lazzarotti A, Ambresin A, Gabrielle PH, Creuzot-Garcher C. Temperature Excursion of Intravitreal Anti-VEGF Agents During Home Storage. *JAMA Ophthalmol*. 2025 Jan 16. doi: 10.1001/jamaophthalmol.2024.5884. Epub ahead of print. PMID: 39820629.
- Turgut F, Somfai GM, Tappeiner C, Hatz K, Mantel I, Ambresin A, Donati G, Guignard V, Nagyová D, Pfister IB, Schild C, Garweg JG. Intravitreal Dexamethasone Implant in Anti-Vascular Endothelial Growth Factor Pretreated Diabetic Macular Edema-A Swiss Cohort Study. *Pharmaceuticals (Basel)*. 2024 Sep 19;17(9):1235. doi: 10.3390/ph17091235. PMID: 39338397; PMCID: PMC11434786.
- Vallée R, Körpe D, Vallée JN, Tsiropoulos GN, Gallo Castro D, Mantel I, Pournaras CJ, Ambresin A. Impact of preocular and ocular circulatory dynamics on the vascular density of retinal capillary plexuses and choriocapillaris. *Graefes Arch Clin Exp Ophthalmol*. 2024 Dec;262(12):3867-3879. doi: 10.1007/s00417-024-06544-4. Epub 2024 Jul 31. PMID: 39083077; PMCID: PMC11608175.
- Vallée R, Körpe D, Vallée JN, Tsiropoulos GN, Gallo Castro D, Mantel I, Pournaras CJ, Ambresin A. Impact of preocular and ocular circulatory dynamics on the vascular density of retinal capillary plexuses and choriocapillaris. *Graefes Arch Clin Exp Ophthalmol*. 2024 Dec;262(12):3867-3879. doi: 10.1007/s00417-024-06544-4. Epub 2024 Jul 31. PMID: 39083077; PMCID: PMC11608175.
- Barbosa M, Pannatier-Schuetz Y, Nascimbeni AC, Castro DG, Owlya N, Ambresin A. Ocular Manifestations in a Context of Primary Hyperparathyroidism: A Report of Two Cases. *Klin Monbl Augenheilkd*. 2024 Apr;241(4):545-548. English. doi: 10.1055/a-2243-4802. Epub 2024 Apr 23. PMID: 38653286.
- Owlya N, Barbosa M, Nascimbeni AC, Pannatier-Schuetz Y, Castro DG, Ambresin A. Torpedo Maculopathy: Case Series of an Underdiagnosed and Rare Condition Using Multimodal Imaging. *Klin Monbl Augenheilkd*. 2024 Mar 26. English. doi: 10.1055/a-2238-7245. Epub ahead of print. PMID: 38176433.
- Pietzuch M, Mantel I, Ambresin A, Tappeiner C, Nagyova D, Donati G, Pfister IB, Schild C, Garweg JG. In-travitreal Dexamethasone as a Rescue for Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration with Persistent Disease Activity and

- High Treatment Demand. *J Ocul Pharmacol Ther.* 2023 Dec 20. doi: 10.1089/jop.2023.0105. Epub ahead of print. PMID: 38117666.
- El Karmy B, Gallo Castro D, Ambresin A, Preventive inflammation management with steroids before re-treatment with anti-VEGF after severe inflammation due to brolucizumab, *Klin Monatsbl Augenheilkd* 2023; 240(4): 556-562.
 - Calci C, Castro DG, Schuetz YP, Mermoud A, Ambresin A. Rapidly Progressive Visual Field Deterioration in a Glaucomatous Patient Treated with Several Anti-VEGF Injections for Neovascular AMD: A Case Re-port. *Klin Monbl Augenheilkd.* 2023 Apr;240(4):478-480. English. doi: 10.1055/a-2004-5664. Epub 2023 Apr 25. PMID: 37164425.
 - Tsiropoulos GN, Vallée R, Calci C, Gallo Castro D, Ambresin A. Patient Perspective on the Monitoring of Their Wet Age-Related Macular Degeneration during Coronavirus Disease 2019: A Retrospective Study. *Medicina (Kaunas).* 2023 Mar 2;59(3):490.
 - Tsiropoulos GN, Vallee R, Gallo Castro D, Ambresin A. The importance of monitoring wet age-related macular degeneration patients during Coronavirus disease 19 pandemic: A retrospective study of as-sessment of functional and structural outcomes. *J Fr Ophtalmol.* 2022 Jul 6;45(8):852–9.
 - Tsiropoulos GN, Castro DG, Ambresin A, Six Cases of Retinal Vascular Anomalies after Corona-virus Disease 2019: A case Series, *Klin Monbl Augenheilkd.* 2022 Apr;239(4):537-544.
 - Moret E, Ambresin A, Gianniou C, Bijon J, Besse-Hayat C, Bogiatzi S, Hohl D, Spertini F, Mantel I. Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth fac-tors. *Graefes Arch Clin Exp Ophthalmol.* 2022 Mar;260(3):1005-1014.
 - Bravetti GE, Vaudaux J, Pournaras JA, Ambresin A. Persistent Remnants of Dexamethasone In-travitreal Implant Over 24 Months in a Patient Suffering from Anterior and Intermediate Uveitis As-sociated with Macular Edema. *Klin Monbl Augenheilkd.* 2021 Apr;238(4):454-457.
 - Chatzistergiou V, Papasavvas I, Ambresin A, Pournaras JC, Prediction of Postoperative Visual Outcome in Patients with Idiopathic Epiretinal Membrane. *Ophthalmologica.* 2021;244(6):535-542.
 - Zola M, Ambresin A, Zografos L, Optical coherence tomography angiography imaging of a con-genital simple hamartoma of the retinal pigment epithelium. *Retin Cases Brief Rep.* 2021 May 1;15(3):289-293.
 - Chatzistergiou V, Ambresin A, Borruat FX. Markedly Delayed Night Blindness Due to Vitamin A Insuffi-ciency Secondary to Bowel Resection. *Klin Monbl Augenheilkd.* 2021 Apr;238(4):428-430.
 - Chatzistergiou V, Cilliers H, Pournaras JA, Ambresin A. Fovea Plana on Optical Coherence To-mography Angiography: New perspectives. *Retina* 2021 Jul 1;41(7):1541-1546.
 - Gillmann K, Mansouri K, Ambresin A, Bravetti GE, Mermoud A. A Prospective Analysis of iStent Inject Mi-cro-stent Implantation: Surgical Outcomes, Endothelial Cell Density, and Device Position at 12 Months. *J Glaucoma* 2020 Aug;29(8):639-647.
 - Voide N, Mantel I, Ambresin A. Atypical Retro Internal Limiting Membrane Haemorrhage in Homo-zygous Sickel Cell Disease. *Klin Monbl Augenheilkd.* 2020 Apr;237(4):477-479.
 - Chatzistergiou V, Papasavvas I, Escher P, Durig J, Vaudaux J, Pournaras JA, Ambresin A. Opti-cal co-herence tomography analysis of cystoid macular edema in retinal dystrophy treated with oral acetazola-mide: two cases, *Klin Monbl Augenheilkd.* 2020 Apr;237(4):484-486.
 - Kheir V, Ambresin A, Mantel I., Multiple serous pigment epithelial detachments in association with major weight loss: case report and review of the literature. *Retin Cases Brief Rep* 2020 Win-ter;14(1):72-76.
 - Roquelaure D, Rossi DC, Ambresin A, Guex-Crosier Y. Vasculitis and Retrofoveal Choroidal Neo-vessels in a Case of Multifocal Pattern Dystrophy. *Klin Monbl Augenheilkd.* 2019 Apr;236(4):523-525.
 - Sherif M, Berthoud J, Pournaras JA, Ambresin A, OCT-Angiography as a Help in the Diagnosis of a La-ser Pointer Retinal Injury: A Case Report, *Klin Monbl Augenheilkd.* 2019 Apr;236(4):594-597
 - Papasavvas I, Ambresin A, Pournaras JA, Henchoz L, Vaudaux J. Regression of Optic Disc Neo-vascular-ization (NVD) in a Patient with Behçet's Disease Treated with Oral Corticosteroids and Adalimumab (ADA). *Klin Monbl Augenheilkd.* 2019 Apr;236(4):578-580.

- Roemer S, Bergin C, Kaeser PF, Ambresin A. Macular vasculature of children with sickle cell disease compared to healthy eyes using optical coherence tomography angiography. *Retina* 2019 Dec;39(12):2384-2391.
- Nguyen NCI, Fabro F, Ambresin A, Ezziat S, Bergin C, Mazzocato C, Mantel I., Factors associated with pain during intravitreal injection of anti-vascular endothelial growth factor. *Eye (Lond)*. 2018 Sep;32(9):1544-1546.
- Tam EK, Golchet P, Yung M, De Croos FC, Spirn M, Lehmann-Clarke L, Ambresin A, Tsui I., Ischemic central retinal vein occlusion in the anti-vascular endothelial growth factor era,. *Retina* 2018 Feb;38(2):292-298.
- Daruich A, Matet A, Marchionno L, De Azevedo JD, Ambresin A, Mantel I, Behar-Cohen F., Acute central serous chorioretinopathy, Factors Influencing Episode Duration, *Retina*. 2017 Oct;37(10):1905-1915.
- Parvin P, Zola M, Dirani A, Ambresin A, Mantel I., Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept, *Graefes Arch Clin Exp Ophthalmol* 2017 Nov;255(11):2127-2134.
- Kowalczyk L, Matet A, Dirani A, Daruich A, Ambresin A, Mantel I, Spaide RF, Turck N, Behar-Cohen F, Efficacy of intravitreal aflibercept in macular telangiectasia type 1 is linked to the ocular angiogenic pro-file, *Retina* 2017 Dec;37(12):2226-2237.
- Dirani A, Ambresin A, Marchionno L, Decugis D, Mantel I, Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration, *Am J Ophthalmol*. 2015 Oct;160(4):732-8.
- Ambresin A, Borruat FX, [Hypertension and the eye]. *Rev Med Suisse*. 2015 Dec 16;11(499):2366, 2368-72. French.
- Matet A, Daruich A, Dirani A, Ambresin A, Behar-Cohen F, Macular Telangiectasia Type 1: Capillary Density and Microvascular Abnormalities Assessed by Optical Coherence Tomography Angiography, *Am J Ophthalmol*. 2016 Jul;167:18-30.
- Massoungnes S, Dirani A, Ambresin A, Decugis D, Marchionno L, Mantel I., Pigment epithelial detachment response to aflibercept in neovascular age-related macular degeneration refractory to ranibizumab: Time Course and Drug Effects, *Retina*. 2016 May;36(5):881-8.
- Massoungnes S, Borruat FX, Ambresin A, Peripheral Bilateral Telangiectasiae in Multiple Sclerosis Patients Treated with Interferon B1a, *Klin Monbl Augenheilkd*. 2016 Apr;233(4):438-40.
- Jang L, Gianniou C, Ambresin A, Mantel I, Refractory subretinal fluid in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: visual acuity outcome, *Graefes Arch Clin Exp Ophthalmol*. 2015 Aug;253(8):1211-6.
- Gianniou C, Dirani A, Ferrini W, Marchionno L, Decugis D, Deli A, Ambresin A, Mantel I, Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results, *Eye (Lond)*. 2015 Mar;29(3):450-1.
- Ambresin A, Strueven V, Pournaras JA, Painless indirect argon laser in high risk proliferative diabetic retinopathy, *Klin Monbl Augenheilkd*. 2015 Apr;232(4):509-13.
- Dirani A, Mantel I, Ambresin A, Recurrent Macular Edema in Central Retinal Vein Occlusion Treated with Intravitreal Ranibizumab using a Modified Treat and Extend Regimen, *Klin Monbl Augenheilkd*. 2015 Apr;232(4):538-41.
- Ladaïque M, Dirani A, Ambresin A, Long-term follow-up of choroidal neovascularization in pathological myopia treated with intravitreal ranibizumab, *Klin Monbl Augenheilkd*. 2015 Apr;232(4):542-7.
- Lehmann-Clarke L, Dirani A, Mantel I, Ambresin A, The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion, *Klin Monbl Augenheilkd*. 2015 Apr;232(4):552-5.
- Meier PG, Ambresin A, Thirkill CE, Borruat FX, Schalenbourg A. Paraneoplastic vitelliform retinopathy secondary to metastatic melanoma. *Klin Monbl Augenheilkd*. 2015 Apr;232(4):587-9.

CONFERENCES (SINCE 2018)

As invited speaker

- Ambresin A. Adaptive Optics Flood Illumination (AO-FI) Study of Drusen Patterns. 11th Annual Pacific Retina Club & 12th Annual International Retinal Imaging Symposium Meeting; 2025 Jun 5-7; Los Angeles, United States of America.
- Ambresin A, Pannatier-Schuetz Y, Gallo Castro D, Nascimbeni AC, Barry PM, Bekiroglu S, Kitsos-Kalyvianakis K, Crozat B, Bartolomeo N. AI integration in research, clinical setting and medical education: A pilot experience towards age related macular degeneration (AMD) management. Delegation of Roche Pharma Switzerland at the Genolier Innovation Hub; 2025 May 21; Genolier, Suisse.
- Ambresin A. *ICG verstehen und interpretieren*. Ophthalmology Update Refresher; 2025 May 23; Zurich, Switzerland.
- Ambresin A. Introduire l'IA dans les consultations en rétinie : un leurre ou un réel bénéfice ? 14ème Rencontre ophtalmologique Neuchâtel-Fribourg par le Centre Neuchâtelois d'Ophtalmologie (CNO) et l'Hôpital Fribourgeois (HFR); 2025 Mai 8; Morat, Switzerland.
- Ambresin A. Recent therapeutic advances in nAMD and DME : Real world evidence from Switzerland. Key Invited International Speaker for: Retinal Diseases: Towards New Horizons. Roche; 2025 May 03; Tunis, Tunisia.
- Ambresin A. Comparison of Geographic Atrophy (GA) Lesion Measurements and Growth Rates Using Semi-automated and Artificial Intelligence (AI) Software. Speaker for: Ophthalmic Artificial Intelligence Summit 2025. 2025, May 31 2025; Online.
- Bartolomeo N. AI-driven OCT Biomarker Quantification in Naive Neovascular Age-related Macular Degeneration Patients Treated with Aflibercept 8mg. Speaker for: Ophthalmic Artificial Intelligence Summit 2025. 2025, May 31 2025; Online.
- Chitoroaga M, Ambresin A. La DMLA, une thérapie personnalisée. Speaker for: *Retina Suisse* Annual Public Conference; 2025 May 24; Lausanne, Switzerland.
- Bartolomeo N, Ambresin A. *Les complications oculaires du diabète*. Speaker for: 'diabètevaud'; 2025 Apr 3; Lausanne, Switzerland.
- Ambresin A. Pegcetacoplan : « breakthrough » ou « fake news » ? La rétinie en pratique : ce qu'il faut savoir en 2025; Centre Ophtalmologique de la Colline; 2025 Fev 20; Geneva, Switzerland.
- Ambresin A. Theoretical sessions: Imaging of progression biomarkers in geographic atrophy (*Ateliers pratiques : Biomarqueurs de l'atrophie géographique en imagerie : quels indicateurs de progression ?*). VuExplorer Institute, Ophthalmic Imaging: from Theory to Current Practice; 2024 Oct 4; Paris, France.
- Ambresin A. Chair for: Rapid Fire | Poster Flash Session. SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 29; Saint Gallen, Switzerland.
- Maloca P, Blaser F, Ambresin A. Chairs and speakers for: Plenary Symposium: Interactive Cases. SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 29; Saint Gallen, Switzerland.
- Ambresin A, Cohen S, Borruat F-X, Malclès A, Valmaggia C, Schalenbourg A, Grimaldi G. Presenters for: Angiography cases to describe MCQ. In: Workshop: Angiography. SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 28; Saint Gallen, Switzerland.
- Ambresin A. Presenter for: Retinophotography, filters and autofluorescence: what is in it for us? In: Workshop: Angiography. SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 28; Saint Gallen, Switzerland.
- Ambresin A. Chair for: Workshop: Angiography. SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 28; Saint Gallen, Switzerland.
- Patel PJ, Ambresin A, Koh AH, Singer MA, Hill L, Kotecha A, Margaron P. Extended Interval Treatment Outcomes and Potential Q20W Dosing for Treatment of nAMD With Faricimab: a Post Hoc Analysis of the TENAYA/LUCERNE Trials. Invited speaker at: American Society of Retina Specialists (ASRS) Annual Meeting; 2024 July 17-20; Stockholm, Sweden.
- Ambresin A, Khanani AM, Lai TYY, Lim JI, London N, Kotecha A, Margaron P, Patel S, Souverain A, Willis J, Yang M. Pigment Epithelial Detachment Outcomes With Faricimab vs Aflibercept in

- Patients With nAMD: Results From TENAYA/LUCERNE. Invited speaker at: American Society of Retina Specialists (ASRS) Annual Meeting; 2024 July 17; Stockholm, Sweden.
- Ambresin A. Photobiomodulation – New Player on the Ground or Great Business Concept? Augenklinik 17. Augenärztliches Symposium; 2024 Jun 27; Zurich, Switzerland.
 - Ambresin A, Souied E. Moderators for: Pour nos patients, adoptons dès maintenant les pratiques de demain. 130e Congrès International de la Société Française d'Ophtalmologie (SFO); 2024 May 6; Paris France.
 - Ambresin A, Mantel I, Vaclavik V. Experience Exchange, Presentation of Real Cases with Vabysmo. Invited speakers at: Angiopoietin-2 (Ang-2) in Medical Retina Diseases. Swiss Visio Montchoisi; 2024 Feb 1; Lausanne, Switzerland.
 - Ambresin A. Traitement de l'atrophie géographique : résultats des études pivotales Oaks and Derby à 2 ans et premières expériences cliniques en suisse romande. Ophtalmologie: innovations thérapeutiques en rétinie médicale et chirurgicale; 2024 Feb 15; Geneva, Switzerland.
 - Ambresin A. Retinal Vein Occlusion In Young Patients: Is Special Treatment Required? 8th Congress of the Swiss Academy of Ophthalmology (SAoO); 2024 Apr 10-12; Lucerne, Switzerland.
 - Ambresin A. Loosing Vision In Diabetic Maculopathy Without Edema: Does That Make Any Sense? 8th Congress of the Swiss Academy of Ophthalmology (SAoO); 2024 Apr 10-12; Lucerne, Switzerland.
 - Prünke C, Ambresin A. Moderation for: Retina Case Club. 8th Congress of the Swiss Academy of Ophthalmology (SAoO); 2024 Apr 10-12; Lucerne, Switzerland.
 - Ambresin A, Owyla N. Photobiomodulation bei trockener AMD. SVRG Swiss Retina Update 2023, 2023 Nov 30; Zurich, Switzerland.
 - Bechara G, Ambresin A. EPPMA: a propósito de un caso. SCOT JOVE 2023; 2023 Nov 24; Barcelona, Spain.
 - Ambresin A. Workshop given at: Journées de la Rétine Roche (J2R); 2023 Nov 23; Lyon, France.
 - Ambresin A. Dry AMD – Licht am Ende des Tunnels? Lichtblicke 17. Ophthalmologie-Symposium; 2023 Nov 09; Bern, Switzerland.
 - Ambresin A. Imagerie de la DMLA atrophique. Les Mardis de l'imagerie du Centre Ophtalmologique de Rive; 2023 Oct 31; Geneva, Switzerland.
 - Ambresin A. Wet AMD and Faricimab IVI: Fluid Analysis Using OCT in Induction Phase. Conference presentation and moderation at: Ophthalmic Imaging: from Theory to current Practice; 2023 Oct 13; Paris, France.
 - Ambresin A. DMLA : La cécité est-elle encore une fatalité? Conference presentation at: Swiss Visio Montchoisi; 2023 Sep 28; Lausanne, Switzerland.
 - Ambresin A. Faricimab : un "game-changer"? Retour d'expérience. Conference presentation at: DMLA en Pratique; 2023 Sep 8; Paris, France.
 - Giocatni-Aurégan A, Munk M, Ambresin A. Illustrative Cases Presentation: the Answer Was in the Angiography... Spot It! SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2023 Sep 1; Lausanne, Switzerland.
 - Ambresin A. Pick Up the OCT Angiography Findings Requiring Dye Angiography. Chair and speaker for: Plenary Symposium: When should I refer my patient for an angiography? SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2023 Sep 1; Lausanne, Switzerland.
 - Virtual Workshop on Evaluating Vascular Stabilization with Faricimab: Current Status and Future Directions. The Angiogenesis Foundation; 2023 Jul 12-13; Online.
 - Pigment epithelium detachment in age-related macular degeneration. Oftacafé 2023 Retina Symposium; 2023 May 18; Lugano, Switzerland.
 - Dégénérescence maculaire liée à l'âge: nouvelles options thérapeutiques. Retina Suisse 44th Annual Meeting; 2023 Apr 29; Bern, Switzerland.
 - DMLA : La cécité est-elle encore une fatalité ? Clinique de Montchoisi; 2023 Avr 27; Lausanne, Switzerland.
 - Improved retina fluid control with faricimab in phase 3 trials in wet AMD and DME. Symposium d'ophtalmologie, SwissVisio Montchoisi; 2023 Mar 30; Crissier; Switzerland.
 - Traitement de l'atrophie géographique: Le Pegcetacoplan bientôt enregistré en Suisse? Résultats des études pivotales Oaks and Derby; Centre Ophtalmologique La Colline; 2023 Mar 30; Geneva, Switzerland.

- Vabysmo First Line - The Early Results: Own OCT examples of treatment-naïve patients. 7th Congress of the Swiss Academy of Ophthalmology; 2023 Mar 2; Lucern, Switzerland.
- Recommendations for intravitreal injection. 7th Congress of the Swiss Academy of Ophthalmology; 2023 Mar 2; Lucern, Switzerland.
- Influence of Retinal and Choroidal Perfusion Times Measured Using Dye Angiography on Quantitative Analysis of OCT-Angiography. 46th Macula Society Annual Meeting; 2023 Feb 17; Miami, United States of America.
- Cas de DMLA avec mauvaise réponse à l'induction: Que faire ? Journée nationale de la Société Française de Rétine; 2023 Jan 21; Paris, France.
- Y-a-t-il une place pour l'utilisation des corticostéroïdes en intravitréen dans la DMLA exsudative? Colloque sur les nouveaux traitements en rétinopathie médicale et chirurgicale; Centre Ophtalmologique La Colline; 2022 Dec 1; Geneva, Switzerland.
- Comparison perfusion time in fluoresceine angiography/digital values in OCT-Angiography / Comparaison temps de perfusion en angiographie avec produit de contraste et valeurs métriques de l'OCT angiographie. Ophthalmic Imaging Congress, Paris, September 23rd 2022.
- Perfusion choroïdienne et activité sportive, Swiss Visio Symposium "Les beaux yeux du sport", Lausanne, 22 septembre 2022.
- Have we arrived at the end of the road for advancements in nAMD treatment?, Bayer-sponsored symposium at the Virtual COPHY Global Congress, June 2022.
- Ophthalmology and Covid-19: what we have learnt? Forum pour la formation médicale - WebUp Experten - Forum «Update Ophtalmologie» [Zoom event].. 2021 Oct 21; Online.
- Premières expériences avec le Brolucizumab en Suisse. Formation continue en Ophtalmologie, Clinique de la Colline; 2020 Oct; Geneva, Switzerland.
- Traitements de la DMLA humide en Suisse : Place du Brolucizumab, de l'Aflibercept, du Ranibizumab et du Bevacizumab. Formation continue en Ophtalmologie, Clinique de la Colline; 2020 Oct; Geneva, Switzerland.
- Prise en charge de la maculopathie diabétique : laser micropulsé, anti VEGF ou corticoïdes ? Formation continue en Ophtalmologie, Clinique de la Colline; 2020 Oct; Geneva, Switzerland.
- Pachychoroid: A New Classification and Clinical Applications of Relevant Results of Recent Studies SSO; 2020 Aug 27; Lausanne, Switzerland.
- Diagnostic and treatment of inflammatory neo vessels. SAO; 2019 Mar 8; Luzern, Switzerland.
- Sensitivity of OCT angiography in the detection of choroidal neovascularization in wet AMD in relation to anatomical features on SDOCT. Macula Society; 2019 Feb 14; Bonita Springs, United States of America.
- Accord entre l'angiographie avec produit de contraste et l'OCT angiographie dans la DMLA néovasculaire, SFR Paris, 19 janvier 2019.
- Biomarqueurs OCT et pathologies maculaires : sine qua non ? Retina Update, Clinique la Colline; 2019 Jan 31; Genève, Switzerland.
- OCT-A : Quand est-elle vraiment utile ? Retina Update, Clinique la Colline; 2019 Jan 31; Genève, Switzerland.
- Influence of structural SD-OCT characteristics in the detection of choroidal neovascularization due to AMD using OCT angiography. OCT 6th Congress; 2018 Dec; Roma, Italy.
- AOP International. Palais Brongniart; 2018 Dec 14-15; Paris, France.
- When should I refer my patient with AMD? Fall seminar. 2018 Oct 4; Coppet, Switzerland.
- Biomarqueurs d'activité en OCTA de la DMLA néovasculaire [OCT angiography in AMD]. Imaging Symposium, Clinique de la Colline; 2018 Jun 21; Geneva, Switzerland.
- Age-related Macular Degeneration. Clinique de Montchoisi; 2018 May 31; Lausanne, Switzerland.
- Polypoidal Cnv In Caucasian Population. Isopt Clinical; 2018 Mar 1-3; Tel Aviv, Israel.
- Maculopathie diabétique : facteurs thérapeutiques systémiques, anti-VEGF, cortisone et laser. Jeudi de Jules Gonin; 2018 Jan 29; Lausanne, Switzerland.
- Biomarkers in clinical diagnosis of wet AMD; Retina French Society, Prof Coscas; 2018 Jan; Paris, France.

As free paper speaker

- Lai TY, Singer MA, Zhang X, Machewit T, Ambresin A, Wong DT, Korobelnik JF, Zarranz-Ventura J, Leal S. Pigment Epithelial Detachment Outcomes with Aflibercept 8 mg Versus Aflibercept 2 mg in the PULSAR Trial: a 96-Week Post Hoc Analysis. Free paper presented at: American Society of Retina Specialists (ASRS) Annual Meeting; 2025 Jul 30 - Aug 2; Long Beach, United States of America.
- Gale R, Sivaprasad S, Ambresin A, Munk M, Patel PJ, Lanzetta P, Korobelnik JF, Leal S, Machewitz T, Zhang X. Greater and More Durable Fluid Resolution With Aflibercept 8 mg Versus Aflibercept 2 mg in the PULSAR Trial: A 96-Week Post-Hoc Analysis. Free paper presented at: American Society of Retina Specialists (ASRS) Annual Meeting; 2025 Jul 30 - Aug 2; Long Beach, United States of America.
- Gale R, Ambresin A, Munk M, Patel PJ, Lanzetta P, Korobelnik J-F, Sivaprasad S, Leal S, Machewitz T, Zhang X. Higher Fluid Control with Aflibercept 8 mg vs Aflibercept 2 mg During Matched Dosing Period Abstract. Free paper submitted at: Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; 2025 May 4-8; Salt Lake City, United States of America.
- Ambresin A, Chitoroaga M, Bartolomeo N, Mamadou PB, Pannatier YA, Gallo DA, Nascimbeni AA. Comparison of Geographic Atrophy (GA) Lesion Measurements and Growth Rates Using Semiautomated and Artificial Intelligence (AI) Software. Free paper presented at: Macula Society 48th Annual Meeting; 2025 Feb 12-15, Charlotte Harbor, Florida.
- Ambresin A, Chitoroaga M, Bartolomeo N, Mamadou PB, Pannatier YA, Gallo DA, Nascimbeni AA. *Étude comparative de l'atrophie géographique mesurée semi manuellement et par intelligence artificielle dans la DMLA atrophique*. Free paper presented at: Journées nationales de la SFRétime; 2025 Jan 25-26; Paris, France.
- Hashimoto R, Ambresin A, Gibson K, Hill L, Sim DA. Predictors of Faricimab Treatment Interval for Diabetic Macular Edema. Presented at: The Japanese Society of Ophthalmic Diabetology Congress; 2025 Jan 25–26; Naha, Japan.
- Bartolomeo N et al. OCT Biomarker Quantification as Short-Term Outcome Predictors of Intravitreal Faricimab Injections in Naïve Patients with Neovascular Age-Related Macular Degeneration. Free paper presented at: FLORetina 12th International Congress on OCT and OCT angiography (ICOOR); 2024 Dec 5-8; Florence, Italy.
- Ambresin et al. Pigment Epithelial Detachment as Long-term Predictors of Functional and Anatomical Outcomes of Intravitreal Faricimab Injections in Naïve Patients With Neovascular Age-related Macular Degeneration. Free paper presented at: FLORetina 12th International Congress on OCT and OCT angiography (ICOOR); 2024 Dec 5-8; Florence, Italy.
- Lanzetta P, Khanani AM, Ambresin A, Avery R, Chaikitmongkol V, Eter N, Gomi F, Lai TYY, Lim JI, London N, Harrell E, Margaron P, Patel S, Souverain A, Yang M. Reduction in Pigment Epithelial Detachments with Faricimab vs Aflibercept in Patients with Treatment-Naïve nAMD: A TENAYA/LUCERNE Post Hoc Analysis. Free paper presented at: FLORetina 12th International Congress on OCT and OCT angiography (ICOOR); 2024 Dec 5-8; Florence, Italy.
- Ambresin A, Gibson K, Sim D, Hill L. Predictors of Extended Treatment Intervals in Patients with DME Treated With Faricimab in the Phase 3 YOSEMITE/RHINE Trials. Free paper presented at: 24th Congress of European Society of Retina Specialists (EURETINA); 2024 Sep 19-22; Barcelona, Spain.
- Koh AHC, Ambresin A, Patel PJ, Singer M, Dagincourt N, Hill L, Kotecha A, Maragron P. Analysis of Extended Interval Treatment Outcomes, Potential for Q20W Dosing and Predictors of Treatment Durability in nAMD With Faricimab From the TENAYA/LUCERNE Trials. Free paper presented at: 24th Congress of European Society of Retina Specialists (EURETINA); 2024 Sep 19-22; Barcelona, Spain.
- Ambresin A, Pannatier-Schuetz Y, Nascimbeni AC, Gallo Castro D, Barbosa M. 12-month Outcomes of Intravitreal Injections in Naive Neovascular Age-related Macular Degeneration: Durability and Retinal Fluids Analysis Using Artificial Intelligence. Audio-narrated free paper presented at: 24th Congress of European Society of Retina Specialists (EURETINA); 2024 Sep 19-22; Barcelona, Spain.
- Barbosa M, Owlya N, Pannatier-Schuetz Y, Nascimbeni AC, Gallo Castro D, Ambresin A. One-year Outcomes of Switching from Aflibercept to Faricimab in Resistant nAMD: Durability and Reti-

- nal Fluids Analysis Using Artificial Intelligence. Audio-narrated free paper presented at: 24th Congress of European Society of Retina Specialists (EURETINA); 2024 Sep 19-22; Barcelona, Spain.
- Bartolomeo N, Barbosa M, Chitoroaga M, Owlya N, Nascimbeni AC, Pannatier-Schuetz Y, Gallo Castro D, Ambresin A. Short-term Outcomes of Pigment Epithelial Detachment in Neovascular AMD Patients Switched from Aflibercept to Faricimab. Audio-narrated free paper presented at: 24th Congress of European Society of Retina Specialists (EURETINA); 2024 Sep 19-22; Barcelona, Spain.
 - Chitoroaga M, Owlya N, Barbosa M, Nascimbeni AC, Pannatier-Schuetz Y, Gallo Castro D, Ambresin A. Adaptive Optics Transscleral Flood Illumination (AO-TFI) Imaging of Retinal Pigment Epithelium (Rpe): Unveiling Alterations in Dry Amd Retina Using a Novel Segmentation Method. Audio-narrated free paper presented at: 24th Congress of European Society of Retina Specialists (EURETINA); 2024 Sep 19-22; Barcelona, Spain.
 - Khanani AM, Ambresin A, Avery R, Chaikitmongkol V, Eter N, Gomi F, Lai TYY, Lim JI, London N, Harrell E, Margaron P, Patel S, Souverain A, Yang M. Reduction in Pigment Epithelial Detachment (PED) With Faricimab vs Aflibercept: A Subgroup Analysis of Patients with Large and Serous PEDs From the Pooled Phase 3 TENAYA and LUCERNE Trials. Audio-narrated free paper presented at: 24th Congress of European Society of Retina Specialists (EURETINA); 2024 Sep 19-22; Barcelona, Spain.
 - Ferrone P, Ambresin A, Avery R, Chaikitmongkol V, Gomi F, Khanani A, Timothy YYL, Lim JI, London N, Harrell E, Margaron P, Patel S, Singer M, Souverain A, Yang M. Response of Large and Serous Pigment Epithelial Detachment to Faricimab Versus Aflibercept in Patients With nAMD: A Subgroup Analysis from TENAYA and LUCERNE. Free paper presented at: Retina Society 57th Annual Scientific Meeting; 2024 Sep 11-15; Lisbon, Portugal.
 - Barbosa M, Owlya N, Pannatier-Schuetz Y, Nascimbeni AC, Gallo Castro D, Ambresin A. One Switching from Aflibercept to Faricimab in Resistant nAMD: Durability and Fluids Analysis Using Artificial Intelligence. Free paper presented at: 47th Macula Society Annual Meeting; 2024 Feb 7-10; Palm Springs, United States of America.
 - Chaudhary V, Ambresin A, Kotecha A, Willis JR, Souverain A, Shildkrot YE, Swaminathan B, Margaron P. Personalised Faricimab Dosing Increased the Proportion of Patients With nAMD Achieving Q16W Dosing in Year 2 of TENAYA/LUCERNE, While Maintaining Functional and Anatomical Outcomes. Free paper presented at: 127th Annual Meeting of the American Academy of Ophthalmology; 2023 Nov 3-6; San Francisco, United States of America.
 - Chaudhary V, Ambresin A, Kotecha A, Willis JR, Souverain A, Shildkrot YE, Swaminathan B, Margaron P. Personalised Faricimab Dosing Increased the Proportion of Patients With nAMD Achieving Q16W Dosing in Year 2 of TENAYA/LUCERNE, While Maintaining Functional and Anatomical Outcomes. Free paper presented at: Retina Society 56th Annual Scientific Meeting; 2023 Oct 13; Lisbon, Portugal.
 - Analyse des fluides en OCT durant la phase d'induction chez les patients avec DMLA exsudative traités par injection de faricimab en intra-vitréen. Imagerie en Ophtalmologie : de la théorie à la pratique; Institut de Formation en Imagerie Ophtalmologique; 2023 Oct 13; Paris, France.
 - Barbosa M, Owlya N, Nascimbeni A, Pannatier-Schuetz Y, Gallo Castro D, Ambresin A. Short-term outcomes of switching to intravitreal faricimab in patients with treatment-resistant neovascular age-related macular degeneration. Free paper presented at: 23rd Euretina Congress; 2023 Oct 5-8; Amsterdam, Netherlands.
 - K Hatz, A Ambresin, M Schmid, C Prünte, D Barthelmes, T Machewitz, H Allmeier, GM Somfai. Two-year Results From the Swiss Cohort of a Non-interventional Study Investigating Real-world Proactive Dosing Regimens With Intravitreal Aflibercept. Free paper presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2023 Sep 1; Lausanne, Switzerland.
 - Barbosa M, Owlya N, Nascimbeni A, Pannatier-Schuetz Y, Gallo Castro D, Ambresin A. Personalised Faricimab Dosing Increased the Proportion of Patients With nAMD Achieving Q16W Dosing in Year 2 of TENAYA/LUCERNE, While Maintaining Functional and Anatomical Outcomes. Free paper presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2023 Sep 1; Lausanne, Switzerland.
 - Influence of retinal and choroidal perfusion times measured using dye angiography on quantitative analysis of OCT-angiography. Ambresin A, Tsiropoulos GN, Vallée R, Gallo Castro D, Körpe D. IOCS; 2021 Sep 24-26; Euretina; 2021 Sep 9-12; Virtual meeting.

- Tsiropoulos GN, Vallée R, Calci C, Gallo Castro D, Ambresin A. Patients' opinion on the monitoring of their wet age-related macular degeneration during Coronavirus disease 2019 pandemic and on the importance of telemedicine. G.N. Tsiropoulos, R. Vallée, C. Calci, D. Gallo Castro, A. Ambresin. *Euretina*; 2021 Sep 9-12; Virtual meeting.
- Tsiropoulos GN, Vallée R, Gallo Castro D, Ambresin A. The Importance of Monitoring Wet Age-related Macular Degeneration Patients During Coronavirus Disease 2019 Pandemic: A retrospective Study of Assessment of Functional and Structural Outcomes. *Euretina*; 2021 Sep 9-12; Virtual meeting.
- Free paper session at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2021 Aug 27; Saint Gall, Switzerland.
- Ambresin A. The Spectrum of Disorders Related to Pachychoroid: an EDI-OCT Evaluation. *EVER*; 2019 Oct 18; Nice, France.
- Ambresin A. OCT and OCT Angiography-Based Management of AMD: Present Indications for the Use of Fluorescein Angiography. *EVER*; 2019 Oct 18; Nice, France.
- Ambresin A. Imagerie en Ophtalmologie : de la théorie à la pratique; 2019 Oct 4; Paris, France.
- Ambresin A. OCTs in Age-Related Macular Degeneration. *Euretina*; 2019 Sep; Paris, France.
- Ambresin A. Pathogenesis of Retinal Vascular Diseases. *Euretina*; 2019 Sep; Paris, France.
- Ambresin A. Aneurysmal Type 1 Neovascularisation. *Euretina*; 2019 Sep; Paris, France.
- Ambresin A. Reliability of OCTA in the Diagnosis of Fovea Plana. *SFO*; 2019 May 13; Paris, France.
- A Ambresin, S Roemer. SD-OCT et angio-OCT d'une maculopathie moyenne paracentrale aiguë (PAMM) chez un patient drépanocytaire, à propos d'un cas. *SFO*; 2019; Paris, France.
- Papasavvas I, Dirani A, Zola M, Pournaras JA, Ambresin A. Influence of structural SD-OCT characteristics in the detection of choroidal neovascularization due to AMD using OCT angiography. Ambresin A. *Macula Society Annual Meeting*; 2019 Feb; Bonita Springs, United States of America.
- Papasavvas I, Dirani A, Zola M, Pournaras JA, Ambresin A. Influence of structural SD-OCT characteristics in the detection of choroidal neovascularization due to AMD using OCT angiography. *Euretina*; 2018; Vienna, Austria.
- Pournaras JA, Zola M, Papasavvas I, Marchionno L, Ambresin A. Idiopathic epiretinal membrane (ERM) en-face visualisation: comparison of Heidelberg multicolour imaging technique with Optovue en-face OCT. *Euretina*; 2018; Vienna, Austria.

As poster presenter

- Gerendas BS, Ambresin A, Arevalo JF, Gibson K, Sim D, Yang M. Predictors of injection numbers in patients with Diabetic Macular Edema (DME) treated with faricimab personalized T&E in the phase 3 YOSEMITE/RHINE trials. Poster presented at: *Retina Society 58th Annual Meeting*; 2025 Sep 13; Chicago, United-States of America.
- Saad A, Somfai GM, Ambresin A, Ebnetter A, Eandi C, Feltgen N, Hatz K, Menghini M, Munk MR, Weinberger A, Zweifel SA, Schild C, Isabel I, Garweg JG, Grimaldi G. One-year outcomes after switching to faricimab in eyes with pre-treated neovascular age-related macular degeneration: a report from the Swiss Retina Research Network. Poster presented at: *Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting*; 2025 May 4–8, 2025; Salt Lake City, USA.
- Gale R, Ambresin A, Munk M, Patel PJ, Lanzetta P, Korobelnik JF, Sivaprasad S, Leal S, Marchewitz T, Zhang X. Greater and more durable fluid resolution with aflibercept 8 mg versus aflibercept 2 mg in the PULSAR trial: A 96-week post-hoc analysis. Poster presented at: *Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting*; 2025 May 4–8, 2025; Salt Lake City, USA.
- Gerendas BS, Ambresin A, Arevalo JF, Gibson K, Sim D, Yang M. Predictors of extended treatment intervals in patients with DME treated with faricimab in the phase 3 YOSEMITE/RHINE trials. Poster presented at: *Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting*; 2025 May 4–8, 2025; Salt Lake City, USA.
- Somfai GM, Turgut F, Tappeiner C, Hatz K, Mantel I, Ambresin A, Donati G, Vivien G, Nagyová D, Pfister I, Schild C, Garweg J. A Swiss Cohort Study on Intravitreal Dexamethasone Implant in

Eyes with Diabetic Macular Edema Pretreated by Anti-VEGF Drugs. ePoster presented at: 24th Congress of European Society of Retina Specialists (EURETINA); 2024 Sep 19-22; Barcelona, Spain.

- Chitoroaga M, Pannatier-Schuetz Y, Gallo Castro D, Nascimbeni AC, Ambresin A. Long-term follow-up of outer retina microdefects (ORMD) in pachychoroid-associated epitheliopathy: a report of two cases. ePoster presented at: SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 28-30; Online.
- Chitoroaga M, Pannatier-Schuetz Y, Gallo Castro D, Nascimbeni AC, Ambresin A. Spectral Domain Optical Coherence Tomography (SD-OCT) features in a de novo TFAP2A mutation in a child with branchio-oculo-facial (BOF) syndrome. ePoster presented at: SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 28-30; Online.
- Ferrini W, Schorderet DF, Nicopoulos K, Ambresin A. A novel heterozygous compound mutation in ABCA4 gene linked to late-onset Stargardt disease revealed in the differential diagnosis of early AMD. ePoster presented at: SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 28-30; Online.
- N Bartolomeo N, Déglise A, Pannatier-Schuetz Y, Nascimbeni AC, Gallo Castro D, Ambresin A. Retinal Toxicities of Anticancer Drugs: A Case Series. Poster presented at: SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 29; Saint Gallen, Switzerland.
- Chitoroaga M, Perez Y, Owlya N, Barbosa M, Nascimbeni AC, Pannatier-Schuetz Y, Gallo Castro D, Ambresin A. Adaptive Optics-enhanced Dual Retinal Layer Imaging and Region Reflectivity-based Segmentation: Unveiling Variances in Healthy and Diseased Retina. Poster presented at: Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; 2024 May 5-9; Seattle, United States of America.
- Chitoroaga M, Perez Y, Pannatier-Schuetz Y, Gallo Castro D, Nascimbeni AC, Ambresin A. Spectral Domain Optical Coherence Tomography (SD-OCT) Features in a De Novo TFAP2A Mutation in a Child With Branchio-oculo-facial (BOF) Syndrome. Poster presented at: Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; 2024 May 5-9; Seattle, United States of America.
- Owlya N, Hebben A, Barbosa M, Gallo Castro D, Nascimbeni AC, Pannatier-Schuetz Y, Ambresin A. Functional and Anatomical Outcomes of Patients Treated With Intravitreal Aflibercept for Refractory Diabetic Macular Edema Switched to Faricimab: an Interim Analysis. Poster presented at: 23rd Euretina Congress; 2023 Oct 5-8; Amsterdam, Netherlands.
- Bechara Ghobril A, Pournaras J-A, Ambresin A. Increased Relevance of Clinical and SD-OCT Cardinal Signs Recognition in Patients With the Underdiagnosed Macular Telangiectasia Type 2 (MacTel) Disease. Poster presented at: 23rd Euretina Congress; 2023 Oct 5-8; Amsterdam, Netherlands.
- Barbosa M, Calci C, Owlya N, Pannatier-Schuetz Y, Gallo Castro D, Nascimbeni AC, Ambresin A. Acute Intraocular Pressure Elevations Following Intravitreal Anti-VEGF Injections in Patients With Wet AMD: a Preliminary Report. Poster presented at: 23rd Euretina Congress; 2023 Oct 5-8; Amsterdam, Netherlands.
- Ambresin A, Hock Chaun Koh AHC, Singer M, Tadayoni R, Hill L, Souverain A, Kotecha A, Margaron P. The Potential for Q20W Dosing With Faricimab and Extended Treatment Outcomes in Neovascular Age-Related Macular Degeneration: a Post Hoc Analysis of the Pivotal TENAYA/LUCERNE Trials. Poster presented at: 23rd Euretina Congress; 2023 Oct 5-8; Amsterdam, Netherlands.
- Owlya N, Nascimbeni A, Pannatier-Schuetz Y, Gallo Castro D, Ambresin A. Torpedo Maculopathy: Cases Series Presentation of an Underdiagnosed Rare Condition Using Multimodal Imaging. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress 2023; 2023 Aug 30 - Sep 1; Lausanne, Switzerland.
- Owlya N, Hebben A, Barbosa M, Gallo Castro D, Nascimbeni AC, Pannatier-Schuetz Y, Ambresin A. Functional and Anatomical Outcomes of Patients Treated With Intravitreal Aflibercept for Refractory Diabetic Macular Edema Switched to Faricimab: an Interim Analysis. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress 2023; 2023 Aug 30 - Sep 1; Lausanne, Switzerland.
- Hatz K, Ambresin A, Schmid M, Prünke C, Barthelmes D, Machewitz T, Allmeier H, Márk Somfai G. Two-year Results From the Swiss Cohort of a Non-interventional Study Investigating Real-world Proactive Dosing Regimens With Intravitreal Aflibercept in Patients With nAMD: XTEND

Study. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress 2023; 2023 Aug 30 - Sep 1; Lausanne, Switzerland.

- Barbosa M, Pannatier-Schuetz Y, Gallo Castro D, Nascimbeni A, Ambresin A. Ocular Manifestations in a Context of Primary Hyperparathyroidism: a Report of Two Cases. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress 2023; 2023 Aug 30 - Sep 1; Lausanne, Switzerland.
- Owlya N, Nascimbeni A, Pannatier-Schuetz Y, Gallo Castro D, Ambresin A. Torpedo Maculopathy: Cases Series Presentation of an Underdiagnosed Rare Condition Using Multimodal Imaging. Poster presented at: 129e Congrès international de la Société Française d'Ophtalmologie (SFO); 2023 May 6-8; Paris, France.
- Hebben A, Ambresin A. Analyse qualitative en SD-OCT de la réponse thérapeutique immédiate après un switch par faricimab hors indication chez des patients souffrant de néovaisseaux choroïdiens récidivants sous maculaires secondaires à une chorioretinopathie séreuse centrale. Poster presented at: 129e Congrès international de la Société Française d'Ophtalmologie (SFO); 2023 May 6-8; Paris, France.
- Bechara Ghobril A, Pournaras J-A, Ambresin A. Increased Relevance of Clinical and SD-OCT Cardinal Signs Recognition in Patients With the Underdiagnosed Macular Telangiectasia Type 2 (MacTel) Disease. Poster presented at: 129e Congrès international de la Société Française d'Ophtalmologie (SFO); 2023 May 6-8; Paris, France.
- Barbosa M, Pannatier-Schuetz Y, Gallo Castro D, Nascimbeni A, Ambresin A. Ocular Manifestations in a Context of Primary Hyperparathyroidism: a Report of Two Cases. Poster presented at: 129e Congrès international de la Société Française d'Ophtalmologie (SFO); 2023 May 6-8; Paris, France.
- Vallée R, Ambresin A. Cardiovascular Risk Prediction by Artificial Neural Networks Using Dye-based Angiography and OCT Angiography Data. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2022 Aug 24-26; Basel, Switzerland.
- El Karmy B, Daniela Gallo Castro D, Ambresin A. Retreatment of Recurrent Wet AMD With an Alternative Intravitreal Anti-VEGF Drug After Ocular Inflammation Following Intravitreal Brolucizumab Injection : About Two Cases. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2022 Aug 24-26; Basel, Switzerland.
- Calci C, Gallo Castro D, Mermoud A, Ambresin A. Rapidly Progressive Visual Field Deterioration in a Glaucomatous Patient Treated With Several Anti-VEGF Injections for Neovascular AMD: a Case Report. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2022 Aug 24-26; Basel, Switzerland.
- Calci C, Gallo Castro D, Mermoud A, Ambresin A. Rapidly Progressive Visual Field Deterioration in a Glaucomatous Patient Treated With Several Anti-VEGF Injections for Neovascular AMD: a Case Report. Poster presented at: 128e congrès international de la Société Française d'Ophtalmologie (SFO); 2022 May 7-9 May; Paris, France.
- Monitoring wet Age related Macular Degeneration patients during Coronavirus disease 2019 pandemic: A retrospective study of assessment of functional and structural outcomes. Georgios N. Tsiropoulos, Rodolphe Vallée, Daniela Gallo Castro, Aude Ambresin. EVER, Nice, 30 September – 2 October 2021.
- Patient opinion on the monitoring of their wet age related macular degeneration during coronavirus disease 2019 pandemic and on the importance of telemedicine. Georgios N. Tsiropoulos, Rodolphe Vallée, Coraline Calci, Daniela Gallo Castro, Aude Ambresin. EVER, Nice, 30 September – 2 October 2021.
- Tsiropoulos GN, Vallée R, Gallo Castro D, Ambresin A. Monitoring Wet Age-related Macular Degeneration Patients During Coronavirus Disease 2019 Pandemic: a Retrospective Study of Assessment of Functional and Structural Outcomes. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2021 Aug 26-27; Saint Gall, Switzerland.
- Meduri E, Tsiropoulos GN, Ribi C, Ambresin A. Efficacy of Tocilizumab in Stabilizing Post-Surgical Inflammatory Refractory Macular Edema: a Report of Two Cases. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2021 Aug 26-27; Saint Gall, Switzerland.
- Pappasavas I, Ambresin A. Bilateral Ocular Melanocytosis-like Fundus Presentation in Patients With Sectorial Relative Pachychoroid: Case Reports of Six Patients. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2019 Aug 30; Interlaken, Switzerland.

- Chatzistergiou V, Ambresin A. Optical Coherence Tomography Analysis of Cystoid Macular Edema in Retinal Dystrophy Treated With Oral Acetazolamide: 2 Cases. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2019 Aug 30; Interlaken, Switzerland.
- Voide N, Ambresin A. Atypical Retro Internal Limiting Membrane Hemorrhage in Homozygous Sick Cell Disease. Poster presented at: SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2019 Aug 30; Interlaken, Switzerland.
- Zola M, Ambresin A, Munier F. Bilateral vascular anomalies in Coats disease suggest concurrent retinal vascular disease. ARVO; 2019; Vancouver, Canada.
- Sherif M, Berthoud J, Ambresin A. OCT-Angiography as a help in the diagnosis of a laser pointer retinal injury. OCTA congress; 2018 Dec; Rome, Italy.
- Voide N, Mantel I, Ambresin A. Atypical retro internal limiting membrane hemorrhage in homozygous sickle-cell disease: a case report. EPOS; 2018; Oslo, Norway.
- Papasavvas I, Ambresin A, Pournaras J-A, Henchoz L, Vaudaux J. Regression of optic disc neovascularization in a patient with Behçet's disease treated with oral corticosteroids and adalimumab. SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2018; Fribourg, Switzerland.
- Ambresin A, Bergin C, Naso S. Comparison of SD OCT and OCTA biomarkers of activity in wet AMD. SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2018; Fribourg, Switzerland.
- Vasculitis and subfoveal choroidal neovessels in a case of Multifocal Pattern Dystrophy. Roquelauze D, Rossi D, Ambresin A, Guex Crosier Y. SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2018; Fribourg, Switzerland.
- Zola M, Ambresin A, Borruat FX, Mantel I. Natural History of PAMM. SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2018; Fribourg, Switzerland.
- Sherif M, Berthoud J, Ambresin A. OCT-Angiography as a help in the diagnosis of a laser pointer retinal injury. SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2018; Fribourg Switzerland.

As speaker in industry sponsored symposiums

- Ambresin A. Aflibercept 8mg – first experiences in the treatment of nAMD and DME. Bayer Advisory Board Meeting; 2024 Nov 20; Lausanne, Switzerland.
- Ambresin A. Virtual Faricimab Advisory Committee Meeting; 2024 Dec 2; Online.
- Ambresin A. Apellis Advisory Board; 2024 Dec 12; Bern, Switzerland.
- Ambresin A. Roche Advisory Board; 2024 Nov 26; Bern, Switzerland.
- Ambresin A, Bartolomeo N, Chitogara M. Integrating Retinal Discovery clinics in a real-world setting: addressing AMD & GA. Retinal Discovery Distributor's Meeting; 2024 Nov 10; Bern, Switzerland. Webinar version available at: <https://youtu.be/4bOcWsaaUbw>.
- Hlekamp N, Ambresin A, Nicholson L, Engelbert M. Revolutionizing First-Line Treatment with Vabysmo. Invited speakers in: Lunch Symposium organized by Roche. SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 29; Saint Gallen, Switzerland.
- Feltgen N, Somfai GM, Ambresin A. Panel discussion. Invited speakers in: Lunch Symposium organized by Apellis. SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 29; Saint Gallen, Switzerland.
- Ambresin A. GA Patient Management: Practical Considerations. Invited speaker in: Lunch Symposium organized by Apellis. SOG/SSO Swiss Society of Ophthalmology 117th Annual Congress; 2024 Aug 29; Saint Gallen, Switzerland.
- Ambresin A. Bayer Advisory Board Meeting on Aflibercept 8mg in Retinal Care. 24th Euretina Congress; 2024 Sep 19; Barcelona, Spain.
- Ambresin A. Moderator for: Astellas Advisory Board Meeting; 2024 Sep 19; 24th Euretina Congress; 2024 Sep 19-22; Barcelona, Spain.
- 130e Congrès International de la Société Française d'Ophthalmologie (SFO); 2024 May 6; Paris France. Moderator for: Symposium Apellis - *Pour nos patients, adoptons dès maintenant les pratiques de demain.*

- 130e Congrès International de la Société Française d'Ophtalmologie (SFO); 2024 May 5; Paris France. Moderator for: Symposium Apellis - *Quelles avancées pour les patients atteints d'atrophie géographique en 2024 ?*
- Get Together with John Kitchens: My Personal Experience with 8 Mg Aflibercept. Bayer Vital Germany; 2024 Mar 18; Online.
- Bayer Advisory Board on 8 mg Aflibercept Launch; 2024 Apr 19-21; Vienna, Austria.
- Ambresin A. Chair for: Apellis InBooth educational session: Geographic Atrophy Contest. 8th Congress of the Swiss Academy of Ophthalmology (SAoO); 2024 Apr 10-12; Lucerne, Switzerland.
- Menghini M, Ambresin A. Vabysmo: Discovering chANGe with Ang-2 in Clinical Practice. Lunch symposium sponsored by Roche. 8th Congress of the Swiss Academy of Ophthalmology (SAoO); 2024 Apr 10-12; Lucerne, Switzerland.
- Ambresin A. Chair for: Lunch symposium sponsored by Bayer. 8th Congress of the Swiss Academy of Ophthalmology (SAoO); 2024 Apr 10-12; Lucerne, Switzerland.
- Ambresin A. Traitement de l'atrophie géographique : résultats des études pivotales Oaks and Derby à 2 ans et premières expériences cliniques en suisse romande. Conference at: Ophtalmologie: innovations thérapeutiques en rétinie médicale et chirurgicale; 2024 Feb 15; Geneva, Switzerland.
- Bayer Advisory Board on 8 mg Aflibercept; 2024 Feb 5; Online.
- Bayer Regional Advisory Board on 8 mg Aflibercept; 2023 Dec 6; Lausanne, Switzerland.
- Roche Regional Advisory Board for Ophthalmology; 2023 Nov 22; Lausanne, Switzerland.
- Bayer Advisory Board on 8 mg Aflibercept; 2023 Nov 14; Lausanne, Switzerland.
- Latest Data For 8mg And Real 8 Mg Clinical Experiences. Bayer Global Advisory Board at the 23rd Euretina Congress; 2023 Oct 6; Amsterdam, Netherlands.
- Roche National Advisory Board on Ang-2 Differentiation in Real-World; 2023 Sep 26; Bern, Switzerland.
- Phase III Clinical Data in Geographic Atrophy. Chair and speaker for: Towards a New Era in Geographic Atrophy (GA) Treatment: Insights and Outlook Lunch symposium organised by Apellis. SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2023 Sep 1; Lausanne, Switzerland.
- First Hand Experience with Vabysmo. Plenum of National and International Physicians at a Roche-organized Global Event. Discover Change Summit; 2023 Jun 23-24; Athens, Greece.
- Geographic Atrophy (GA) and Challenges in Cost Reimbursement. Apellis Advisory Board; 2023 Jun 6; Lausanne, Switzerland.
- Faricimab: réflexion basée sur l'évidence pour le switch et données de vraie vie. Bayer Board National Rétine; 2023 May 5; Paris, France.
- Apellis Geographic Atrophy Days; 2023 Apr 14-15; Rome, Italy.
- Bayer National Advisory Board on 8 mg Aflibercept; 2023 Jan 23; Bern, Switzerland.
- Apellis Swiss Medical Advisory Board on Geographic Atrophy; 2022 Dec 1; Bern, Switzerland.
- Roche Advisory Board for Ophthalmology; 2022 Nov 24; Lausanne, Switzerland.
- Bayer Advisory Board on Aflibercept; 2022 Nov 7; Lausanne, Switzerland.
- Changing Treatment Landscape – How to Start With the New Options Based on a Risk-benefit Approach? Bayer National Advisory Board on Aflibercept; 2022 Jun 20; Switzerland.
- Novartis Symposium. Swiss Academy of Ophthalmology (SAoO); 2022 Mar 3; Lucerne, Switzerland.
- New Therapeutic Approaches in nAMD and DME. Roche Advisory Board; 2022 Jan 24-25; Switzerland.
- Virtual Diabetic Macular Edema (DME). Novartis Advisory Board; 2021 Nov 25; Switzerland.
- Bayer Advisory Board; 2021 Nov 18; Lausanne, Switzerland.
- Highlights from the EURETINA 2021. Novartis Advisory Board; 2021 Sep 29; Switzerland.
- Bayer Scientific Board; 2020 Oct; Switzerland.
- Pearls in the Anti-VEGF Therapy of Retinal Diseases: From Theory to Practice Differences in Mode of Action of Current Treatments, Actual Insights into Switching Drugs in wAMD. Lunch symposium organized by Bayer. SOG/SSO Swiss Society of Ophthalmology Annual Congress; 2020 Aug 28; Lausanne, Switzerland.

- Brolucizumab: From Pivotal Studies to Real World Experience. Lunch symposium organized by Novartis. SOG/SSO Swiss Society of Ophtalmology Annual Congress; 2020 Aug 27; Lausanne, Switzerland.
- Novartis Scientific Board; 2020 Jun; Switzerland.

COLLABORATIONS

- Hon. Prof Vanderberg and Prof. Hilal Lashuel. Associate Professor of Life Sciences, Director of the Laboratory of Chemical Biology of Neurodegeneration, Brain Mind Institute, Swiss Federal Institute of Technology, EPFL; Lausanne, Switzerland.
- RetinAI Medical AG; Bern, Switzerland.
- Timothé Laforest. CEO, EarlySight; Geneva, Switzerland.

HONORS

- Barbosa M, Ambresin A. Benign Lobular Inner nuclear layer Proliferation (BLIPs) of the retina associated with congenital hypertrophy of the retinal pigment epithelium. In: Ultra-widefield IMAGE OF THE MONTH. Retinal Physician; 2023 May.
- Chitoroaga N, Ambresin A, Petrovic A. Challenges in Managing Post-lyell Ocular Complications: Addressing Severe Ocular Surface Disease During Intravitreal Injections. Nominee for: Théa Trophy Contest; 2023.